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Abstract 
Background: Biphenotypic sinonasal sarcoma is a recently described malignancy showing dual 
differentiation with both myogenic and neural elements. Due to its histologic similarities to other 
sinonasal malignancies, it is a diagnostic challenge.  
 
Objective: To report a case of Biphenotypic sinonasal sarcoma and to consolidate data and provide a 
comprehensive review regarding pathological differences between Biphenotypic sarcoma and other 
sinonasal malignancies and diagnostic modalities used for Biphenotypic sarcoma. 
Material and methods: A systematic review of all cases of biphenotypic sinonasal sarcoma was performed 
using electronic databases (PubMed and Medline). Data collected included age, gender, symptoms, sub-
site of origin, immunophenotyping, metastasis, recurrence, treatment, duration of follow up and survival 
outcomes. 
 
Results: Ninety-five cases of biphenotypic sarcoma were found with mean age at diagnosis of 52.36 years 
(Range, 24-87 years). Female to male ratio was 2.27:1. Extra-sinonasal extension was present in 28%. 
Immunophenotyping revealed that S-100 and SMA were consistently positive while SOX-10 was 
consistently negative. PAX3-MAML3 fusion [t (2; 4) (q35; q31.1)] was the most common genetic 
rearrangement. Surgical excision with or without adjuvant radiotherapy was the most frequent treatment 
modality used. Recurrence was observed in 32% of cases with follow up. None of the cases reported 
metastasis. Three patients had died at the time of publication that included one case with intracranial 
extension. 
 
Conclusion: Biphenotypic sarcoma is distinct sinonasal malignancy with unique clinicopathological 
features. Testing involving a battery of myogenic and neural immunomarkers is essential for diagnostic 
confirmation and is a clinically useful endeavor when clinical suspicion is high.  
  
Introduction 
Sinonasal malignancies are a diagnostic and therapeutic challenge due to the sheer histologic diversity 
and proximity to vital structures like the orbit, cranial nerves, and brain. Early diagnosis is often 
confounded by non-specific symptoms which can be mistaken for benign disease. In addition, there exists 
a considerable degree of histologic overlap among distinct sinonasal malignancies, making diagnosis on 
biopsy challenging. One of the most recent sinonasal malignancies described in the latest WHO edition of 
head and neck tumors is biphenotypic sinonasal sarcoma (BSNS).1 The existence of this unique tumor 
was initially suspected based on earlier work,2,3 followed by a few publications detailing 
clinicopathological features only recently reported.4-10 
 
Perhaps, most characteristic of BSNS is the presence of both myogenic and neural differentiation. 
Pathologic descriptions of BSNS include a highly cellular spindle cell neoplasm with monomorphic 
picture on histology with S-100 and actin positivity on immunophenotyping. Additional pathological 
studies including immunophenotyping and fluorescent in situ hybridization (FISH) studies confirm the 
diagnosis. Clinically, the tumor is slowly progressive with a predilection for upper aero digestive tract. 
However, locally aggressive spread may occur in up to half of the affected patients.4 
 
Most of the reported cases of BSNS have been isolated cases or small case series.  Efforts are ongoing to 
consolidate all relevant data regarding BSNS with special emphasis on diagnostic modalities. Here we 
present a case of a patient treated for BSNS and review the current literature concerning this newly 
identified tumor, with emphasis on clinicopathologic features and diagnostic modalities. 
 
Materials and methods: 
An exhaustive literature review was performed using electronic databases (PubMed and Medline) and all 
relevant publications in English that included cases of BSNS were included.  An additional manual search 
was performed by cross-referencing the retrieved cases. The following search terms were used: 
“sinonasal”, “sinus” “nasal”, “biphenotypic” and “sarcoma”. The first case of BSNS was described in 
2012. Therefore, studies published before 2012 were excluded. Diagnosis of BSNS requires both 
pathological analysis and immunophenotyping of the sample. Cases with incomplete, insufficient, 
inconsistent diagnostic information and doubtful diagnosis were excluded. The following data were 
collected from all cases: age, gender, symptoms, sub site of origin, immunotyping, metastasis, recurrence, 
treatment, duration of follow up and survival outcomes at the time of publication of the respective case.  
 
Case Report: 
We report  an otherwise healthy 53 year old gentleman who presented for evaluation of progressive 
unilateral nasal obstruction and anosmia for several months. Examination revealed a large left sided soft 
tissue mass.  Imaging showed complete opacification of the left frontal sinus with bony erosion of the 
medial orbit and skull base. Office biopsy was most consistent with a low-grade spindle cell carcinoma, 
with immunohistochemistry stains positive for S100 and negative for actin, desmin, and neurofilament. 
Though initially, a peripheral nerve sheath tumor was one of the differential diagnosis, as the patient had 
no clinical features of Neurofibromatosis-1, it was unlikely. He was taken to the operating room for an 
endoscopic endonasal approach for resection of the tumor. Intraoperatively, the tumor was found to be 
highly vascular and locally invasive, with destruction of superior portions of the lamina papyracea and 
exposure of periorbita within the nasal cavity on the left side. Tumor was adherent to the periorbita and, 
given the presumed benign nature of the tumor, a small amount of residual tumor was left attached to the 
periorbita. There was further destruction of the superior septum and portions of the cribriform plate, with 
gross tumor within the right ethmoid cavity and abutting the right orbit. Frozen pathology specimens 
remained consistent with a spindle cell tumor. His postoperative course was uneventful. 
 
Final pathology returned as Biphenotypic sinonasal sarcoma with focal rhabdomyoblastic differentiation. 
This BSNS was characterized by a moderate to highly cellular proliferation of spindle cells arranged in 
interwoven fascicles (Figure 1). Occasional staghorn vessels and focal bone infiltration by the tumor 
(features not shown) were also present. The histologic appearance of the tumor was compatible with a 
low to, at most, intermediate grade lesion, reflecting  the lack of mitotic activity or tumor necrosis, and 
the absence of significant cellular or nuclear pleomorphism. Based upon this histomorphology, the 
pathologic differential diagnosis included BSNS, schwannoma, solitary fibrous tumor and synovial 
sarcoma. In contrast to schwannomas, which classically display strong, diffuse S-100 staining, our tumor 
showed focal, patchy S100 positivity, a pattern commonly reported in BSNSs. Lack of cytokeratin 
(CAM5.2, cytokeratins 7 and 8) and CD34 staining in our tumor helped to rule out synovial sarcoma and 
solitary fibrous tumor, respectively. Additional immunohistochemical stains were positive for vimentin, 
and were negative for MELAN-A, HMB-45, and Calretinin. Lastly, the tumor displayed strong, 
widespread positive nuclear staining for MyoD1, which further supported the diagnosis of biphenotypic 
sinonasal sarcoma with rhabdomyoblastic differentiation. Furthermore, FISH analysis was performed 
which showed presence of PAX3-MAML3 fusion protein. 
He was referred to both Radiation Oncology and Medical Oncology and underwent a PET-CT, showing 
no distant disease. He was again taken to the operating room for complete oncologic resection of the 
residual tumor which had intentionally been left attached to the left periorbita. The periorbita was resected 
via a transconjunctival orbitotomy, but the orbit, including the extraocular muscles, was spared. Margins 
were negative for tumor at the conclusion of the case. Again, recovery was uneventful. Multidisciplinary 
discussion was held, and the decision was made for adjuvant external beam radiotherapy (60 Gy in 30 
fractions).  Adjuvant chemotherapy was deemed unnecessary.  He is doing well and free of disease at 
follow up. 
Results: 
Ninety-five cases of BSNS were documented in seven published reports.4-10 Mean age at diagnosis was 
52.36 years (range, 24-87 years). Female preponderance was noted (69%) with a female to male ratio of 
2.27:1. On comparing the age distribution of patients, it was noticed that majority (27%) belonged to 5th 
decade (Table1). The most common symptoms observed were mainly related to mass effect of tumor 
(Table 2). Out of twenty-eight cases in whom past history was recorded, four had a history of sinonasal 
surgery for presumed benign disease. In more than one-third of cases (37%), the site of origin was not 
clearly stated (Table 3). Of the rest, paranasal sinuses (PNS) were the most common site (30%), and 
ethmoid sinus was involved most frequently involved PNS, either alone or in combination with other 
PNS. Approximately almost one third of patients (28%) showed extra-sinonasal extension (Table 3). 
Mean size of the lesion was 3.95 cm. Radiological studies (reported in seven cases) revealed 
heterogeneous enhancing mass, hyperostotic bone formation (osteitis), and local destruction of lamina 
papyracea and skull base including cribriform plate. PET scans showed a low uptake (SUV max of 2.9).5  
 
Pathologically, both neural and muscle immunomarkers were utilized to establish the diagnosis (Table 4).  
FISH studies were performed in 66% cases (Table 5). On analyzing the clinical differences between the 
classical and novel gene rearrangements, it was observed that novel mutations involving PAX 3 were 
more likely to occur in younger patients (median age 35 years), while double negative fusions were more 
common in older patients (median age 60 years), in comparison to classical genetic rearrangements 
(median age 47 years).8 Additionally, the classical PAX3-MAML3 genetic rearrangement were more 
common in female as compared to male patients.8 It is worth noting that 2 cases of PAX-NCOA1 fusion 
protein and one case of PAX-FOXO1 fusion protein showed a distinctive rhabdomyoblastic 
differentiation6,7 while cytogenetic analysis of the 3 remaining cases of rhabdomyoblastic differentiation 
and one case of fibroblastic differentiation was not performed.4,5 Cytogenetic analysis were performed in 
2 other cases which reveled t(2,4) translocation.4 Reverse transcriptase-polymerase chain reaction (RT-
PCR) for synovial sarcoma fusion transcripts (SYT-SSX1 AND SYT-SSX2) was negative in all cases 
tested (21 cases).4,10  
 
Among cases with reported treatment (8%, 8 cases), surgical excision with or without post-operative 
radiotherapy was the most common modality used (Table 6). After completion of the treatment, 36% 
(34/95) were followed for a mean duration of 4.61 years (range, 3 months - 28 years). Recurrence was 
observed in 32% (11/34) for whom follow up data was available, out of which 82% were females with a 
mean age of 49 years (Range, 24-69 years). Though primary disease was more common in PNS (Table 3), 
64% of cases who showed recurrence had primary disease of nasal cavity, either alone or with PNS 
involvement (Table 7). None of the cases reported metastasis. The average duration until appearance of 
recurrence was 2.4 years. An additional patient showed evidence of disease on imaging at one year 
follow-up which was suspected to be residual disease.8  
 
On follow up, it was noticed that three patients had succumbed to disease, and all three were reported to 
have developed recurrence. One of these cases had evidence of recurrence twice during the duration of 
follow up, once at 2 years and the next at 4 years after completion of primary treatment.9 Intracranial 
involvement was present during the second recurrence and patient expired 8 months after diagnosis of the 
same. Non-tumor-related causes were reported for the other two cases.4   
 
Discussion: 
The most distinctive feature of BSNS is the presence of dual differentiation with both myogenic and 
neural elements. Owing to low mitotic rate of the spindle cells present, it is also known as low-grade 
sarcoma or spindle cell sarcoma.11 In some cases, as with our patient, rhabdomyoblastic differentiation 
(11%) has also been reported.6,7,12 In one of the cases of BSNS, fibroblastic differentiation has been 
observed5 and it is currently unknown whether fibroblastic differentiation is a precursor to myogenic 
differentiation or whether it represents a distinct subset of patients with BSNS with unique local cellular 
factors leading to fibroblastic differentiation.  
 
Another distinctive pathological feature is the entrapment of hyperplastic respiratory epithelium leading 
to gland or cyst formation (so-called “pseudo-gland formation”) seen in 70% cases. In addition, hyper-
cellularity, bone invasion (20%), hemangiopericytoma-like staghorn vessels, overlapping cells, 
herringbone patterns have been documented.13 Although, some of these pathological characteristics of 
BSNS are distinct, none are exclusive to BSNS.  
 
A variety of sinonasal malignancies, including cellular schwannoma (CS), low grade malignant peripheral 
nerve sheath tumor (LG-MPNST), leiomyosarcoma (LMS), fibrosarcoma (FS), synovial sarcoma (SS), 
glomangiopericytoma (GPC), solitary fibrous tumor (SFT), inverted papilloma (IP), fibromatosis and 
malignant melanoma, may pathologically mimic BSNS. The differentiating pathological characteristics of 
BSNS in comparison to other common sinonasal malignancies has been depicted below (Table 9).4,14,15 
However, diagnosis of BSNS based on pathological features alone is not possible due to the potential for 
pathological overlap.  Therefore, immunophenotyping is a pre-requisite for diagnosis.  
 
Immunophenotypical analysis reveals that S-100 (neural marker) and SMA (myogenic marker) are 
consistently positive in BSNS while, SOX-10 (neural crest differentiation marker) is consistently 
negative.6 Comparison of immunomarkers of BSNS with other sinonasal tumors (Table 8) reveals the 
differences in distribution of these markers.16-24 Due to patchy distribution of some of these markers, one 
of the major pitfalls of immunophenotyping is a missed diagnosis of BSNS owing to small sample size or 
sampling errors. However, analyzing the overall morphological picture helps to narrow down the 
differential diagnoses. For instance, in our case, triton tumor (variant of MPNST) was one of the closest 
differentials. Though these tumors exhibit common immunomarker positivity, histologically MPNST 
exhibits a high mitotic rate and often tumor necrosis.  BSNS on the other hand, displays a low to, at most, 
intermediate grade histology with a low (in this case 0%) mitotic rate and an absence of tumor necrosis. 
Additionally, the patient had no features of Neurofibromatosis-1 on clinical exam. 
 
Molecular studies, mainly the FISH analysis, are a new addition to the list of diagnostic modalities used 
for BSNS. In some cases, determination of a particular genetic aberration can confirm the diagnosis of 
BSNS. PAX3-MAML3 fusion [t (2; 4) (q35; q31.1)] is a classical fusion protein found in 79-96% of 
cases.11,13 In fact, our case is the first case of PAX3-MAML3 fusion protein positive BSNS with 
rhabdomyoblastic differentiation. PAX 3 rearrangement is a characteristic finding, as it has not been seen 
in any other sinonasal malignancy. It is the most frequent genetic rearrangement described in BSNS. 
PAX-3 is a transcription factor, which stimulates commitment along both neural crest and skeletal muscle 
cell lines, and blocks terminal differentiation.2,25-28 It also has a significant role in nasal development. In 
difficult cases, in order to determine the histopathological diagnosis, the absence of a genetic aberration 
can also help in the diagnosis of BSNS. For instance, monophasic synovial sarcoma (SS) cannot be 
differentiated conclusively from BSNS on pathological or immunophenotypic analysis. In such 
cases, absence of a SS18 translocation on molecular studies confirms the diagnosis of BSNS as this 
translocation is required for SS.4,11  
 
However, molecular studies too, are not without pitfalls. Though a large number of BSNS exhibit the 
classical PAX3-MAML3 rearrangement, a subset of biphenotypic sinonasal sarcomas show no PAX3 or 
MAML3 involvement (Table 5). Therefore, reports of FISH analysis need to be read with caution.  In 
fact, several novel genetic rearrangements seen in BSNS have been recently defined (Table 5).11 
Therefore, owing to the absence of immunophenotyping and lack of appropriate molecular studies in the 
past, there is a possibility that a majority of the cases of BSNS have been incorrectly labelled as other 
sinonasal tumors. Therefore, it would not be surprising if the prevalence of genuine BSNS is larger than 
reported.  
 
When compared to other head and neck sarcomas , BSNS is seen to be clinicopathologically distinct.5,12,29-
33 Interestingly, alveolar rhabdomyosarcoma, which is often characterized by a high metastatic potential 
and worse prognosis, shares a similar genetic aberration (involving PAX 3 gene) as compared to 
BSNS.8,34 Difference in the cell of origin and its microenvironment could be the reason for the stark 
clinicopathological dissimilarities between the two malignancies.8,35 In this context, it is essential to 
determine if BSNS truly represents a sarcoma or is a sarcomatous variant of a fibrous tumor. In addition, 
further studies are required to investigate the molecular basis and cellular factors leading to the formation 
of this tumor. 
 
Clinically, BSNS is generally considered to behave less aggressively than other more common sinonasal 
malignancies such as sinonasal undifferentiated carcinoma or poorly differentiated squamous cell 
carcinoma. As with the case presented here, treatment regimens may be consequently de-escalated (e.g. 
treated with adjuvant radiation alone, rather than with adjuvant chemoradiotherapy) in appropriate cases. 
However, given the paucity of information on treatment among published cases, very little can be 
conclusively suggested regarding optimal treatment modality. Therefore, it is suggested that future case 
reports on BSNS should include complete treatment details for meaningful comparison between different 
treatment strategies. 
 
Conclusion: 
BSNS is distinct sinonasal malignancy with dual differentiation. Its clinical behavior, pathological 
features, immunophenotypic presentation, standard of care and prognostic outcomes are entirely different 
not only from other non-sarcomatous sinonasal malignancies, but also from other head and neck 
sarcomas.  
 
 
 
 
 
 
 
 
 
References 
1. Thompson LDR, Franchi A. New tumor entities in the 4th edition of the World Health 
Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull 
base. Virchows Arch. 2017; 
2. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J. 1993;12(6):2361-7. 
3. Gil-benso R, López-ginés C, Carda C, et al. Cytogenetic and molecular findings related to 
rhabdomyosarcoma. An analysis of seven cases. Cancer Genet Cytogenet. 2003;144(2):125-33. 
4. Lewis JT, Oliveira AM, Nascimento AG, et al. Low-grade sinonasal sarcoma with neural and 
myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol. 2012;36(4):517-
25. 
5. Powers KA, Han LM, Chiu AG, Aly FZ. Low-grade sinonasal sarcoma with neural and myogenic 
features--diagnostic challenge and pathogenic insight. Oral Surg Oral Med Oral Pathol Oral 
Radiol. 2015;119(5):e265-9. 
6. Huang SC, Ghossein RA, Bishop JA, et al. Novel PAX3-NCOA1 Fusions in Biphenotypic 
Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. Am J Surg Pathol. 
2016;40(1):51-9. 
7. Wong WJ, Lauria A, Hornick JL, Xiao S, Fletcher JA, Marino-enriquez A. Alternate PAX3-
FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosomes Cancer. 
2016;55(1):25-9. 
8. Fritchie KJ, Jin L, Wang X, et al. Fusion gene profile of biphenotypic sinonasal sarcoma: an 
analysis of 44 cases. Histopathology. 2016;69(6):930-936. 
9. Rooper LM, Huang SC, Antonescu CR, Westra WH, Bishop JA. Biphenotypic sinonasal 
sarcoma: an expanded immunoprofile including consistent nuclear β-catenin positivity and 
absence of SOX10 expression. Hum Pathol. 2016;55:44-50. 
10. Cannon RB, Wiggins RH, Witt BL, Dundar Y, Johnston TM, Hunt JP. Imaging and Outcomes for 
a New Entity: Low-Grade Sinonasal Sarcoma with Neural and Myogenic Features. J Neurol Surg 
Rep. 2017;78(1):e15-e19. 
11. Wang X, Bledsoe KL, Graham RP, et al. Recurrent PAX3-MAML3 fusion in biphenotypic 
sinonasal sarcoma. Nat Genet. 2014;46(7):666-8. 
12. Wenig BM. Recently described sinonasal tract lesions/neoplasms: considerations for the new 
world health organization book. Head Neck Pathol. 2014;8(1):33-41.  
13. Purgina B, Lai CK. Distinctive Head and Neck Bone and Soft Tissue Neoplasms. Surg Pathol 
Clin. 2017;10(1):223-279.  
14. Riddle NN, Gardner JM. The New Kids on the Block: Recently Characterized Soft Tissue 
Tumors. Surg Pathol Clin. 2015;8(3):467-91.  
15. Johncilla M, Jo VY. Soft tissue tumors of the sinonasal tract. Semin Diagn Pathol. 2016;33(2):81-
90. 
16. Miettinen M, Mccue PA, Sarlomo-rikala M, et al. Sox10--a marker for not only schwannian and 
melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 
5134 tumors. Am J Surg Pathol. 2015;39(6):826-35.  
17. Kang Y, Pekmezci M, Folpe AL, Ersen A, Horvai AE. Diagnostic utility of SOX10 to distinguish 
malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial 
sarcoma. Mod Pathol. 2014;27(1):55-61.  
18. Karamchandani JR, Nielsen TO, Van de rijn M, West RB. Sox10 and S100 in the diagnosis of 
soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20(5):445-50. 
19. Heffner DK, Gnepp DR. Sinonasal fibrosarcomas, malignant schwannomas, and "Triton" tumors. 
A clinicopathologic study of 67 cases. Cancer. 1992;70(5):1089-101. 
20. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of 
spindle cell lesions: analysis of a series and review of the literature. Histopathology. 
2007;51(4):509-14. 
21. Terada T, Kato T. Sinonasal-type hemangiopericytoma of the nasal cavity and paranasal sinus. Int 
J Clin Oncol. 2012;17(2):169-73. 
22. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous 
and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 
t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol. 2002;26(11):1434-40.  
23. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for 
rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg 
Pathol. 2001;25(9):1150-7. 
24. Thompson, Mietttien, Wenig. Sinonasal type hemangiopericytoma: A Clinicopathologic and 
Immunophenotypic analysis of 104 cases. Am J Surg Path. 2003 
25. Lang D, Lu MM, Huang L, et al. Pax3 functions at a nodal point in melanocyte stem cell 
differentiation. Nature. 2005;433(7028):884-7. 
26. Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, Kumar P. Pax genes in embryogenesis and 
oncogenesis. J Cell Mol Med. 2008;12(6A):2281-94.  
27. Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev 
Biochem Mol Biol. 2009;44(2-3):85-97. 
28. Nakazaki H, Reddy AC, Mania-farnell BL, et al. Key basic helix-loop-helix transcription factor 
genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. Dev Biol. 
2008;316(2):510-23.  
29. Wu AW, Suh JD, Metson R, Wang MB. Prognostic factors in sinonasal sarcomas: analysis of the 
surveillance, epidemiology and end result database. Laryngoscope. 2012;122(10):2137-42. 
30. Szablewski V, Neuville A, Terrier P, et al. Adult sinonasal soft tissue sarcoma: analysis of 48 
cases from the French Sarcoma Group database. Laryngoscope. 2015;125(3):615-23.  
31. Charest M, Hickeson M, Lisbona R, Novales-diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT 
imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J 
Nucl Med Mol Imaging. 2009;36(12):1944-51.  
32. Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of (18)F-FDG-
PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008;22(7):603-9.  
33. Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-
analysis. J Nucl Med. 2003;44(5):717-24.  
34. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are 
prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. 
J Clin Oncol. 2002;20(11):2672-9. 
35. Barr FG, Zhang PJ. The impact of genetics on sarcoma diagnosis: an evolving science. Clin 
Cancer Res. 2006;12(18):5256-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures: 
 
Figure 1: Histological features of Biphenotypic sinonasal sarcoma (BPSS). (A) The tumor exhibits a 
proliferation of uniform spindle cells in fascicles arranged in a herringbone pattern (hematoxylin-eosin 
stain, original magnification x400). (B) The tumor cells show focal patchy S100 expression, which 
supports a diagnosis of BPSS (anti-S100, original magnification x400). This immunophenotype differs 
from the diffusely positive S100 expression that would be expected in a Schwannoma. (C) The tumor 
displayed rhabdomyosarcomatous differentiation, as evidenced by the strong, focal, nuclear MyoD1 
expression (anti-MyoD1, original magnification x400; insert x1000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables: 
Table 1: Details of age distribution  
Age at diagnosis N (%) 
Less than 20 years 00 (00.00) 
21-30 years 03 (03.15) 
31-40 years 11 (11.57) 
41-50 years 26 (27.36) 
51-60 years 11 (11.57) 
61-70 years 11 (11.57) 
71-80 years 05 (05.26) 
81-90 years 03 (03.15) 
Unknown 25 (26.31) 
Total 95 (100.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Details of frequently reported clinical symptoms  
Nasal complaints Nasal obstruction, rhinorrhea (may be purulent), Anosmia, Nasal congestion, 
Recurrent epistaxis 
Sinus complaints Frequent sinus infections refractory to antibiotics, facial pain, facial 
discomfort/pressure, supra orbital swelling 
Ophthalmological 
complaints 
Diplopia, proptosis, Blurred vision, periorbital pressure, epiphora 
 
Oral complaints Dysgeusia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Details of site of origin of tumor in the sinonasal area and extra-sinonasal extension 
Site  Sub site N (%) 
 
Nasal Cavity (NC)  
Septum 02 
Lateral wall 02 
Unknown 14 
Total 18 (18.94%) 
 
 
Paranasal sinuses (PNS)  
Ethmoid  15 
Frontal  04 
Sphenoid 01 
Maxillary 00 
Ethmoid + Frontal 05 
Ethmoid + Sphenoid 01 
Unknown 03 
Total 29 (30.52%) 
 
Nasal cavity and paranasal 
sinuses 
NC + Ethmoid 09 
NC + Frontal + Ethmoid 03 
NC + Sphenoid 01 
Total 13 (13.68%) 
Unknown Unknown 35 (36.84%) 
Site of extra-sinonasal extension (ESE) 
Orbit 12 (44.44%) 
Cribriform plate / Skull base 10 (37.03%) 
Intracranial 04 (14.81%) 
Oropharynx 01 (03.70 %) 
Total* 27 (100.0%) 
  
* The total number of cases with extra-sinonasal extension (ESE) could be lower than this number as 
occasionally the same patient has ESE in different sub-sites. For instance, one of the patients10 had ESE to 
3 different sub sites- orbit, skull base and intra cranial area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Details of Immunophenotyping studies  
Markers/Ref. 4 5 6 7 8 9 10 Total % 
S-100 28/28 1/1 7/7 1/1 42/43  11/11 3/3 93/94 98.93 
SMA 23/25 0/1 5/5  1/1 39/42 11/11 3/3  82/88 93.18 
MSA 14/16 0/1 4/4     0/1 18/21 85.71 
Beta catenin  1/1    10/11  11/12 91.66 
EMA 3/19 0/1  0/1   0/1 3/22 13.63 
Myo-D1   3/7  11/33   14/40 35.00 
Myogenin / Myf4  0/1 1/7 1/1 2/23  3/10  0/1 7/43 16.27 
Desmin 4/20  0/1 4/7  1/1 16/36 4/11 2/3 31/79 39.24 
Keratin 2/22 0/1 2/5    0/2 4/30 13.33 
CD34 5/21  1/5    0/2 6/28 21.42 
SOX10 
 
 0/7   0/11 0/1 0/18 00.00 
Vimentin  1/1      1/1 100.0 
h-Caldesmon  1/1      1/1 100.0 
Factor XIIIa 
 
    8/10  8/10 80.00 
Calponin   1/1     1/1 100.0 
TLE1    1/1    1/1 100.0 
ER/PR  0/1      0/1 00.00 
 *Each box denotes the proportion of positive cases for that particular immunomarker. The numerator 
denotes the number of positive cases while the denominator denotes the number of cases tested. 
 
 
 
 
Table 5: Details of FISH analysis 
Sl. No Types of rearrangements / References  6 7 8 9 N (%)  
1 Classical rearrangement (PAX3-MAML3) 4  24 5 33 (52.38%) 
2  
Novel  rearrangements 
(Either PAX3 or MAML3) 
PAX3-FOXO1  1 3  04 
PAX3-NCOA1 2  1 1 04 
PAX3-X  1  11 2 14 
MAML3- X    1  01 
Total     23 (36.5%) 
3 Double negative (Both PAX3 and MAML3 absent)   4  04 (6.34%) 
4 Failed testing / Tissue not available    3 03 (4.76%) 
Total 7 1 44 11 63 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Details of treatment modalities utilized  
Treatment of primary disease 
1 Open approach Cranial (Anterior) skull base resection10 01 
 
 
2 
 
Endoscopic anterior 
skull base resection  
with cerebrospinal fluid (CSF) leak repair and 
frozen section of dural margins5 
01 
With adjuvant chemoradiotherapy7 01 
with lamina papyracea excision10 01 
3 Surgical treatment  With adjuvant chemoradiotherapy6  01 
No additional details available8 01 
4 Orbital exenteration9 02 
5 Treatment pending10* 01 
6 Details not known4,6,8,9 86 
Treatment of recurrence 
1 Open approach 
(Extended Craniofacial 
resection) 
Without adjuvant radiotherpay4 02 
With orbital exenteration and adjuvant 
radiotherapy4 
01 
2 Endoscopic anterior 
skull base resection 
With dura resection and frozen section of dural 
margins with CSF leak repair 10 
01 
3 Details not known4,6,9 07 
*As patient had severe aortic stenosis, treatment was pending at the time of publication as patient had 
undergone valve replacement surgery. 
 
 
 
 
Table 7: Details of cases which developed recurrence 
Sl. No Reference Age (Years) Gender Site of primary Time of recurrence Outcome 
1 4 52 F PNS (F / E) NK I 
2 4 69 F NC NK D 
3 4 69 M NC / PNS (E) NK D 
4 4 38 F NC / SB NK F 
5 4 47 F PNS (E) / SB NK I 
6 4 24 F PNS (E / S) NK I 
7 4 45 F NC / SB NK F 
8 6 46 F NC (Septum) 36 months F 
9* 9 39 F PNS (F) 24 and 48 months D 
10 9 46 F NC (Septum) 36 months F 
11 10 67 F NC / PNS (F / E) 17 months F 
* Recurrence was seen twice.  
I =Inadequate follow up after treatment of recurrent disease; F: Free of disease at last follow up after 
treatment of recurrence; D: Dead at the time of last follow up; NC: Nasal cavity; PNS: Paranasal sinuses; 
E: Ethmoid sinus; F: Frontal sinus; S: Sphenoid sinus; SB: Skull base. 
 
 
 
 
 
 
 
 
Table 8: Comparison of distribution of immunomarkers between BSNS and other sinonasal malignancies 
 BSNS CS LG-MPNST LMS FS SS GPC SFT 
SOX -10 - +/- +      
Beta catenin +(F,W) - - - - +(F)/- +(D,S)  
S100 +(D/F) +(D) +(F) - - +/- - - 
Myogenin + - -(+)* +(D)  +/- -  
Factor XIIIa +     -   
Desmin +/-(MF/P) - -(+)* +(D)   -  
SMA +(MF/P) - -(+)* +(D) - +/-  - 
CK (AE1/AE3) +/-(F)     +(F)   
TLE 1      +   
EMA +/-(F)     +(F)/-   
CD34 +(F)       +(D,S) 
STAT6        + 
h-Caldesmon +(D) -       
MSA +(MF/P)        
SS18-SSX 
fusion 
-     +   
 
CS: Cellular Schwannoma; LG-MPNST: Low grade malignant peripheral nerve sheath tumor; LMS: 
Leiomyosarcoma; FS: Fibrosarcoma; SS: Synovial sarcoma GPC: Glomangiopericytoma; SFT: Solitary 
fibrous tumor; W: Weakly positive; S: Strongly positive; MF: Multifocal; D: Diffuse; P: Patchy; S: F: 
Focal; +: Positive; -: Negative; + / _: Positive or negative; 
*Positive if rhabdomyoblastic differentiation present (Triton tumor) 
 
Table 9: Comparison of pathological characteristics of BSNS with other similar sinonasal malignancies 
 
         
                             
   
 
 
                                                                                                                                  
   
 
 
 
 
 
 
 
Table 9: It depicts comparison of pathological features between BSNS and its differential diagnosis. The 
inner central table denotes BSNS and the outer tables on both sides denote other sinonasal malignancies. 
Each characteristic in the central table highlight the starkly dissimilar features in BSNS in comparison to 
other malignancies. LG-MPNST: Low-grade malignant peripheral nerve sheath tumor  
 
 
LG-MPNST 
High rate. 
Variable cellularity   
Solitary fibrous tumor 
Variable cellularity   
Dense, ropy collagen 
Cellular Schwannoma 
Well circumscribed 
Poorly 
circumscribed 
Mitosis, necrosis and 
nuclear atypia rare 
Uniform 
cellularity 
Slender, wiry 
collagen 
Thin, wavy nuclei 
and thin cells. 
Overlapping long 
nuclei, spindle cells 
Short fascicles 
of collagen 
Pseudo-glands 
Inverted papilloma 
Sinonasal glands 
Fibrosarcoma 
 Long fascicles 
of collagen 
Glomangiopericytoma 
Epithelioid cells, rounded  
non-overlapping nuclei 
Perivascular hyalinization 
Leiomyosarcoma 
Plump nuclei,  
Box car cells 
